login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
All US stocks
All Canadian stocks
All European stocks
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Account
Disclaimer
Affiliate
Contact
Privacy
ONCONOVA THERAPEUTICS INC (ONTX) Stock News
NASDAQ:ONTX -
US68232V8019
-
Common Stock
0.9953
USD
0 (-0.47%)
Last: 4/2/2024, 8:00:02 PM
0.9012
USD
-0.09 (-9.45%)
After Hours:
4/2/2024, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ONTX Latest News, Press Relases and Analysis
All
Press Releases
24 days ago - By: The Motley Fool
- Mentions:
TRAW
Traws Pharma Posts Q2 Revenue Jump
a year ago - By: Onconova Therapeutics, Inc.
Traws Pharma Announces New Employee Inducement Grants
a year ago - By: Onconova Therapeutics, Inc.
Traws Pharma Announces New Employee Inducement Grants
a year ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
2 years ago - By: Benzinga
Onconova Therapeutics's Earnings: A Preview
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics’ Rigosertib Poster Selected for AACR 2024
2 years ago - By: Benzinga
- Mentions:
CPHI
PACB
ONMD
SNES
...
12 Health Care Stocks Moving In Thursday's After-Market Session
2 years ago - By: Seeking Alpha
Onconova stock falls 10% on preclinical data for lymphoma drug (NASDAQ:ONTX)
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma
2 years ago - By: InvestorPlace
- Mentions:
JTAI
NXTP
VIRC
PSTX
...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics’ Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. Other CDK4/6i’s
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Present at NobleCon19, Noble Capital Markets’ Nineteenth Annual Emerging Growth Equity Conference
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Third Quarter 2023 Financial Results
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Provide Corporate Update and Announce Third Quarter 2023 Financial Results on November 14, 2023
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Expands Leadership Team with Two Key Appointments
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Expands Leadership Team with Two Key Appointments
2 years ago - By: Onconova Therapeutics, Inc.
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
2 years ago - By: Onconova Therapeutics, Inc.
Promising Preclinical Narazaciclib Data Presented at MCL Meeting
2 years ago - By: Onconova Therapeutics, Inc.
Encouraging Rigosertib Data Presented at EADV as Late Breaker
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Present a Late-Breaking Abstract on Rigosertib at the 2023 EADV Congress
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics to Participate at the H.C. Wainwright 25th Annual Global Investment Conference
2 years ago - By: Onconova Therapeutics, Inc.
Onconova Therapeutics Reports Corporate Update and Announces Second Quarter 2023 Financial Results
Please enable JavaScript to continue using this application.